Microsoft Restores Microsoft 365 Services After Widespread Outage 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
GAITHERSBURG, Md., May 11, 2017 -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as Senior Director of Clinical Development in September 2015, with a specific focus on advancing Novavax’ programs within emerging infectious disease. Previously, Dr. Cummings served as the Director for Global Emerging Infections Surveillance and Response System (GEIS) at the Armed Forces Health Surveillance Branch (AFHSB), Director, Translational Medicine Branch & Division of Regulated Activities at Walter Reed Army Institute of Research (WRAIR) and Consultant to the U.S. Army Surgeon General for all Medical Research and Development.
“In his short tenure at the company, James has shown his ability to constructively organize, motivate and manage complex development programs,” said Stanley C. Erck, President and CEO. “His demonstrated expertise in product development and leadership capabilities earned James the appointment of Project Lead for our nanoparticle influenza vaccine candidate development program, and promotion to Vice President. I am thrilled to congratulate James for his successes here at Novavax.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Director, Investor Relations [email protected] 240-268-2000
